MedTrace Logo

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

NCT05171075 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 417

Last updated 2026-04-17

No results posted yet for this study

Summary

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Conditions

Interventions

BIOLOGICAL

Abelacimab

Abelacimab 150 mg

DRUG

Dalteparin

Dalteparin 200 IU/kg/day followed by 150 IU/kg/day

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-27
Primary Completion
2026-04-10
Completion
2026-04-10
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Canada
  • China
  • Czechia
  • France
  • Germany
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Netherlands
  • Norway
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05171075 on ClinicalTrials.gov